|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
FridayECTRIMS Congress 2013: NOVARTIS, SANOFI AND BIOGEN TOUT NEW MS DRUG RESEARCH
ECTRIMS Congress 2013
New data is rolling out at the European Committee for Treatment and Research in Multiple Sclerosis annual meeting this week, with the new slate of oral treatments in the spotlight, along with a lineup of older injectables and experimental drugs. So far, one common theme is this: Early treatment equals better results. In any disease, the earlier a drug can get into the mix of possible treatments, the better. So, it's no surprise that Sanofi ($SNY) and Biogen Idec ($BIIB) each touted data on early use of their MS treatments Aubagio (teriflunomide) and Tysabri (natalizumab), respectively. Read more » Labels: Aubagio (teriflunomide), Copaxone (Glatiramer Acetate), Ectrims 2013, FDA, Gilenya (Fingolimod)m Novartis, Teva, Tysabri (natalizumab) |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||